Search

Author/Creator Ericsson, Hans

1. Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator. (22nd April 2018)

Authors:
Erlandsson, Fredrik; Albayaty, Muna; Chialda, Ligia; Ericsson, Hans; Amilon, Carl; Nelander, Karin; Jansson‐Löfmark, Rasmus; Wernevik, Linda; Kjaer, Magnus; Bamberg, Krister; Hartleib‐Geschwindner, Judith
Journal:
British journal of clinical pharmacology
Issue:
Volume 84:Number 7(2018.)
Page Start:
1486
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability. Issue 3 (2nd December 2019)

Authors:
Ericsson, Hans; Nelander, Karin; Heijer, Maria; Kjaer, Magnus; Lindstedt, Eva‐Lotte; Albayaty, Muna; Forte, Pablo; Lagerström‐Fermér, Maria; Skrtic, Stanko
Journal:
Clinical pharmacology in drug development
Issue:
Volume 9:Issue 3(2020)
Page Start:
411
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study. Issue 2 (30th October 2019)

Authors:
Whittaker, Andrew; Kragh, Åsa M.; Hartleib‐Geschwindner, Judith; Albayaty, Muna; Backlund, Anna; Greasley, Peter J.; Heijer, Maria; Kjaer, Magnus; Forte, Pablo; Unwin, Robert; Wernevik, Linda; Ericsson, Hans
Journal:
Clinical and translational science
Issue:
Volume 13:Issue 2(2020)
Page Start:
275
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers. Issue 4 (18th February 2019)

Authors:
Gan, Li‐Ming; Lagerström‐Fermér, Maria; Ericsson, Hans; Nelander, Karin; Lindstedt, Eva‐Lotte; Michaëlsson, Erik; Kjaer, Magnus; Heijer, Maria; Whatling, Carl; Fuhr, Rainard
Journal:
British journal of clinical pharmacology
Issue:
Volume 85:Issue 4(2019)
Page Start:
762
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction. Issue 3 (2nd May 2021)

Authors:
Nelander, Karin; Lagerstrom‐Fermer, Maria; Amilon, Carl; Michaëlsson, Erik; Heijer, Maria; Kjaer, Magnus; Russell, Muir; Han, David; Lindstedt, Eva‐Lotte; Whatling, Carl; Gan, Li‐Ming; Ericsson, Hans
Journal:
Clinical and translational science
Issue:
Volume 14:Issue 3(2021)
Page Start:
812
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. A novel 'bottom-up' physiologically based pharmacokinetic (PBPK) model of itraconazole and its metabolites: the importance of enzyme kinetics and protein binding. Issue 1 (January 2019)

Authors:
Garcia, Luna Prieto; Janzén, David; Kanebratt, Kajsa; Ericsson, Hans; Lennernäs, Hans; Lundahl, Anna
Journal:
Drug metabolism and pharmacokinetics
Issue:
Volume 34:Issue 1(2019)Supplement
Page Start:
S70
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗